Plus Therapeutics, Inc. (PSTV)

NASDAQ: PSTV · Real-Time Price · USD
0.4497
-0.0102 (-2.22%)
At close: Sep 4, 2025, 4:00 PM
0.4733
+0.0236 (5.25%)
Pre-market: Sep 5, 2025, 4:33 AM EDT
-2.22%
Market Cap44.64M
Revenue (ttm)5.32M
Net Income (ttm)-19.03M
Shares Out 99.26M
EPS (ttm)-1.20
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,579,965
Open0.4600
Previous Close0.4599
Day's Range0.4428 - 0.4869
52-Week Range0.1634 - 2.3100
Beta0.66
AnalystsStrong Buy
Price Target7.88 (+1,652.28%)
Earnings DateAug 14, 2025

About PSTV

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary live... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 21
Stock Exchange NASDAQ
Ticker Symbol PSTV
Full Company Profile

Financial Performance

In 2024, Plus Therapeutics's revenue was $5.82 million, an increase of 18.54% compared to the previous year's $4.91 million. Losses were -$12.98 million, -2.54% less than in 2023.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for PSTV stock is "Strong Buy." The 12-month stock price target is $7.88, which is an increase of 1,652.28% from the latest price.

Price Target
$7.88
(1,652.28% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

HOUSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advance...

2 days ago - GlobeNewsWire

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

HOUSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform ...

9 days ago - GlobeNewsWire

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting tox...

17 days ago - GlobeNewsWire

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advance...

20 days ago - GlobeNewsWire

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeut...

21 days ago - GlobeNewsWire

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

CNSide® can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations

21 days ago - GlobeNewsWire

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large private healthcare systems Company will expand testing services and broaden r...

5 weeks ago - GlobeNewsWire

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Payment is part of $17.6 million award granted for leptomeningeal cancer targeted radiotherapeutic development program Payment is part of $17.6 million award granted for leptomeningeal cancer targeted...

6 weeks ago - GlobeNewsWire

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Presentation by trial principal investigator at the 2025 SNO/ASCO CNS Metastases Conference Plus will also host an educational symposium with leading experts titled, “Reimagining Your Approach to Lept...

7 weeks ago - GlobeNewsWire

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) focus on the rapidly evolving area of central nervous system metastases

2 months ago - GlobeNewsWire

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Substantial clinical need expected to facilitate rapid overall trial enrollment Substantial clinical need expected to facilitate rapid overall trial enrollment

2 months ago - GlobeNewsWire

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Primary objective to determine optimal dosing schedule for a registrational trial Trial builds on recommended Phase 2 dose determined in completed Phase 1 trial Trial benefits from $17.6M award from t...

2 months ago - GlobeNewsWire

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion Management to host a co...

2 months ago - GlobeNewsWire

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

HOUSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform ...

2 months ago - GlobeNewsWire

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll children with high grade glioma and ependymoma HOUSTON, June 25, 2025 (GLOBE...

2 months ago - GlobeNewsWire

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

Comprehensive restructuring eliminates the potential issuance of up to 1.5 billion shares of common stock Plus Therapeutics files a request to withdraw the related resale registration statement with t...

2 months ago - GlobeNewsWire

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

Company continues to progress both REYOBIQ™ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness HOUSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: ...

3 months ago - GlobeNewsWire

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

HOUSTON, May 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced it received a delinquency notification letter from Nasdaq on May 21, 2025, which indica...

3 months ago - GlobeNewsWire

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

Multiple long-term LM survivors in those patients receiving multiple doses of REYOBIQ RNA sequencing data show early tumor apoptosis and activation of innate immune responses Updated ReSPECT data pres...

4 months ago - GlobeNewsWire

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

HOUSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform t...

4 months ago - GlobeNewsWire

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform...

4 months ago - GlobeNewsWire

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQ New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows prom...

5 months ago - GlobeNewsWire

Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - CFO Conference Call Participants E...

5 months ago - Seeking Alpha

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform...

5 months ago - GlobeNewsWire

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus Th...

6 months ago - GlobeNewsWire